Created by: Karen Ginsbury, MSc, BPharma, CEO, PCI Pharmaceutical Consulting IsraelKaren-Ginsbury_ICHQ9R1-Step2-181122 To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.
Created by: Karen Ginsbury, MSc, BPharma, CEO, PCI Pharmaceutical Consulting IsraelKaren-Ginsbury_ICHQ9R1-Step2-ppt-20211126Download
Created by: Karen Ginsbury, MSc, BPharma, CEO, PCI Pharmaceutical Consulting IsraelKaren-Ginsbury_FDA-draft-guide-risk-mgmt-plans-drug-shortages-may-2022Download
This paper intends to provide guidance on talent planning, with specific emphasis on role clarity. Given the flurry of activity being conducted during capital projects and transitions to operations, developing a talent plan may appear to be somewhat administrative or insufficiently urgent. This often leads site leaders to forego a focused and thoughtful talent planning […]
Your company has received an FDA warning letter, now what? As an organization finds itself in uncharted waters due to inspection results, the leader’s job is to chart a course and speed to re-inspection success without everyone jumping ship. Leaders must remember historical averages for change success hovers between 30-50% (Adam & Danaparamita, 2016; Beer […]
